Evidence map›Paper›PMID 41462013›Full record

ArticleAnnals of clinical and translational neurology2026

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib.

Ashley Jones, Samuele Bonomi, Keith E Stockerl-Goldstein, Randall J Bateman

Abstract readCase Reports
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ashley JonesSaint Louis University School of Medicine, St. Louis, Missouri, USA.
Samuele BonomiDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.ORCID 0000-0001-5799-2416
Keith E Stockerl-GoldsteinDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Randall J BatemanDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

Funding

Anne & Ray CapestrainCommunity Foundation for the Land of LincolnCommunity Foundation Serving West Central Illinois and Northeast MissouriFoundation for Barnes-Jewish HospitalGHR FoundationJTL Family FundMary & Jay SullivanPayne FamilyRichard Frimel & Gary WerthsTracy Family Foundation
6 · The paper itself

Abstract

Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations. He was investigated for dementia and psychiatric disorders but ultimately improved only after discontinuing imatinib. His decompensation years after therapy start, followed by complete and rapid remission, is atypical. We also review the most recent neurobiological findings on the role of tyrosine kinase alterations in dementia and their importance for mood regulation.

Indexed as

Antineoplastic AgentsDementiaImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAgedDiagnosis, DifferentialHumansMaleAntineoplastic AgentsImatinib MesylateProtein Kinase Inhibitorsbehavioral neurologychronic myeloid leukemiadementianeuropsychiatrytyrosin kinase inhibitors

Identifiers

PMID41462013
PMCPMC13071097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.